JPRN-jRCTs031210343已完成未知
Trial for application of individualized oral prebiotics and probiotics supplements on the subjective severity in patients with irritable bowel syndrome; multicenter, open-label non-randomized, single-arm trial - TAILOR-IBS study
Torii Akira0 个研究点目标入组 120 人开始时间: 2021年9月24日最近更新:
适应症
试验速览
- 阶段
- 未知
- 状态
- 已完成
- 发起方
- 入组人数
- 120
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
- 年龄范围
- >= 20age old 至 < 60age old（—）
- 性别
- All
入选标准
- •Patients who meet all of the following criteria are included in this study;
- •1. Patients who are diagnosed with diarrhea-predominant irritable bowel syndrome (IBS-D), constipation-predominant irritable bowel syndrome (IBS-C), or mixed-form irritable bowel syndrome (IBS-M) based on Rome IV diagnostic criteria.
- •2. Male and female aged 20 years or older, and younger than 60 years.
- •3. Subjects whose native language is Japanese.
- •4. Subjects who provide their written consent form to participate in the study.
排除标准
- •Patients who meet any of the following criteria are excluded from the study;
- •1. Patients who took antibiotics or antimicrobial agents within the last 3 months before giving their consent.
- •2. Patients who are diagnosed with gastrointestinal disorders such as inflammatory bowel disease.
- •3. Patients with hisotory of major gastrointestinal surgery such as gastrectomy, gastrointestinal suture, or intestinal resection.
- •4. Patients who have taken antidepressants, antipsychotics, or anxiolytics on a daily basis within the last 3 months before giving their consent (excluding those who take the drugs as needed)
- •5. Patients who take drugs that suppress immune function at giving their consent.
- •6. Patients who take drugs that affect blood glucose or blood pressure at giving their consent.
- •7. Patients with history of allergy against the active ingredients* of the study foods
- •*active ingredients: arabinogalactan, Guar Gum degradant, pectin, delipidated rice bran, inulin, cornstarch, psyllium, bifidobacteria, lactobacillus
- •8. Patients who have a history of cancer in the gastrointestinal organs or who are currently receiving treatment or medications for cancer in the gastrointestinal organs.
- •9. Patients with serious cerebrovascular disease, cardiac disease, hepatic disease, renal disease, gastrointestinal disease, or infectious disease requiring notification
- •10. Patients who are pregnant, breastfeeding, possibly pregnant, or planning to be pregnant.
- •11. Patients who need legal representative for giving their consent.
- •12. Patients who are considered to be unsuitable for participating in this study by investigators.
研究者
相似试验
尚未招募
不适用
A pilot study assessing the effectiveness of oral Propranolol in preventing epistasis in patients with Hereditary Haemorrhagic Telangiectasia.Hereditary Haemorrhagic TelangiectasiaHuman Genetics and Inherited Disorders - Other human genetics and inherited disordersCardiovascular - Diseases of the vasculature and circulation including the lymphatic systemACTRN12619001020178Royal brisbane and Women's Hospital15
尚未招募
不适用
Trial of an Individualised Intervention for the Prevention of Stroke (TIIPS)- using health and wellness coachingtransient ischaemic attack (TIA)Neurological - Other neurological disordersStroke - IschaemicStroke - HaemorrhagicStrokeACTRN12622000939796Auckland University of Technology360
尚未招募
不适用
ROLE OF ORAL APPLICATION OF COLOSTRUM IN IMPROVEMENT OF HEALTH IN PRETERM INFANTSCTRI/2017/03/008031SUDEEP K C128
尚未招募
3 期
Safety & Efficacy of HDNT-072012CTRI/2022/02/040379Himalaya Wellness Company
尚未招募
2 期
A clinical study to assess safety and effectiveness of toothpaste in healthy adult subjectsCTRI/2022/07/043641Himalaya wellness company